Skip to main content
Przejdź do strony domowej Komisji Europejskiej (odnośnik otworzy się w nowym oknie)
polski pl
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
Zawartość zarchiwizowana w dniu 2024-06-25

Application of Mesenchymal stem cells in tumour therapeutic approaches

Cel

New treatment modalities are needed to augment present therapies for metastasising colorectal cancer. The TNF-related-apoptosis-inducing ligand (TRAIL; ApoL2) has been shown to specifically induce cell death in tumour cells, including colorectal cancer cel ls, leaving normal healthy tissue unaffected. Gene therapy approaches using TRAIL have the advantage over bolus injections of recombinant protein, that the cytokine can continuously exert its anti-tumour effect. However, clinical gene therapy applications have been hampered by a combination of side effects and poor delivery. One way to overcome this hurdle is to utilise the functions of stem cells drawn upon by the growing tumour, i.e. tumours require formation of supportive mesenchymal stroma and exogenously delivered mesenchymal stem cells (MSC) preferentially engraft at the tumour sites and contribute to the population of stromal fibroblasts.
Our goal is to transduce MSCs with an expression construct carrying an engineered, secreted version of TRAIL. The MSCs will be transduced ex vivo with Adeno-associated viral (AAV) vectors that are known to facilitate long-term gene expression and trigger no substantial immune responses. The AAV vectors will be optimised for the transduction of MSC by the use of bi-specific antibodies and a bio-selection procedure.
This procedure aims to isolate mutants that show improved transduction of MSC. Finally the TRAIL-loaded MSC will be tested in various colon cancer models for efficacy and safety. In summary we will engineer a combined cell-gene therapy system combining the safety features of AAV and TRAIL and the tumour-delivery potential of MSCs, which we will further enhance by chemokine-guided recruitment to the tumour. In order to reach our goal of combating colon cancer u sing adult stem cells and modern vector technology, I wish to build an international research team at the National University of Ireland, Galway.

Dziedzina nauki (EuroSciVoc)

Słowa kluczowe

Temat(-y)

Zaproszenie do składania wniosków

FP6-2005-MOBILITY-8
Zobacz inne projekty w ramach tego zaproszenia

System finansowania

EXT - Marie Curie actions-Grants for Excellent Teams

Koordynator

NATIONAL UNIVERSITY OF IRELAND GALWAY
Wkład UE
Brak danych
Koszt całkowity
Brak danych